期刊文献+

肺癌组织P-gp、GST-Ⅱ和TOPO-Ⅱ表达及与Ki-67相关性 被引量:6

EXPRESSIONS OF P-gp,GST-Ⅱ AND TOPO-Ⅱ IN LUNG CANCER AND THEIR RELATIONSHIP WITH Ki-67
在线阅读 下载PDF
导出
摘要 目的探讨多药耐药(MDR)基因产物P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶Ⅱ(GST-Ⅱ)、DNA拓扑异构酶(TOPO-Ⅱ)在肺癌组织中的表达及其与细胞核增殖抗原(Ki-67)相关性。方法采用免疫组织化学方法检测63例肺癌组织中P-gp、GST-Ⅱ、TOPO-Ⅱ和Ki-67的表达情况。结果 P-gp、GST-Ⅱ、TOPO-Ⅱ和Ki-67在肺癌组织中的阳性表达率分别为61.9%、63.5%、77.8%和39.7%。P-gp、GST-Ⅱ、Ki-67的表达与肺癌病理组织学分型、分化程度有关(χ2=6.733~22.532,P<0.01)。TOPO-Ⅱ在鳞癌和小细胞癌中的阳性表达率明显高于腺癌(χ2=8.259、4.189,P<0.01、0.05)。两个或两个以上MDR基因产物共表达率合计为90.5%,明显高于单独基因产物P-gp和TOPO-Ⅱ的表达率(χ2=59.660,P<0.01)。P-gp、GST-Ⅱ的表达与Ki-67之间无显著相关性(P>0.05),TOPO-Ⅱ的表达与Ki-67呈明显正相关(r=0.380,P<0.01)。结论 P-gp、GST-Ⅱ、TOPO-Ⅱ在不同肺癌类型中均有不同水平表达,且呈共同表达,它们的表达对肺癌的耐药起重要作用,因此联合检测有助于判断化疗疗效及预后。 Objective To explore the expression of products of multidrug resistance (MDR) gene-P glycoprotein (P-gp), glutathione S epoxide transferase Ⅱ(GST Ⅱ ) and DNA topoisomerase (TOPO-Ⅱ )-in human lung cancer and their correlation with Ki-67. Methods The expressions of P-gp, GST- Ⅱ , TOPO-Ⅱ and Ki-67 in 63 cases of lung cancer were detected by immu- nohistochemical method. Results The positive rates of P-gp, GST-Ⅱ , TOPO-Ⅱ and Ki-67 were 61.9 %, 63.5 %, 77.8 % and 39.7 %, respectively. The expressions of P-gp, GST-Ⅱ , and Ki-67 were correlated with the histological typing and differentiation of the cancer (X2 6. 733-22. 532,P〈0.01). The expression rate of TOPO-Ⅱ in squamous cell carcinoma and small cell cancer was significantly higher than that in adenocarcinoma (Z2 =8. 259,4. 189;P〈0.01,0.05). The coexpression rate of more than one MDR gene products was 90.5 G, which was apparently higher than the expression of single gene product such as P-gp and TOPOⅡ(Z 2 = 59. 660, P 〈0.01). The expressions of P-gp and GST-Ⅱ were not obviously associated with that of Ki-67 (P 〉 0.05), but that of TOPO Ⅱ was positively correlated with Ki-67 (r=0. 380,P〈0.01) Conclusion Different levels of expressions of P-gp, GST Ⅱ , and TOPO Ⅱcan be seen in different-type lung cancer, in pattern of co expression. Their expressions play an important role in lung cancer resistant to chemotherapy. Hence co detection of the expressions conduces to assessment of chemotherapeutic efficacy and prediction of prognosis.
出处 《齐鲁医学杂志》 2013年第1期11-13,16,共4页 Medical Journal of Qilu
基金 青岛市公共领域科技支撑计划项目(11-2-3-2-(3)-nsh)
关键词 肺肿瘤 P糖蛋白 谷胱甘肽转移酶 DNA拓扑异构酶类 Ⅱ型 增殖细胞核抗原 免疫组织化学 lung neoplasms P-glycoprotein glutathione transferase DNA topoisomerases, type Ⅱ proliferating cell nuclear antigen immunohistochemistry
  • 相关文献

参考文献14

  • 1王文苹,季旭明,欧阳兵,王中霞,于华芸,吴智春.逆转肺癌多药耐药的研究进展[J].世界中西医结合杂志,2011,6(9):820-822. 被引量:4
  • 2OLAUSSEN K A, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non small-cell lung cancer and cisplatin based adjuvant chemotherapy[J]. N Engl J Med, 2006,355 (10) :983-991.
  • 3李国仁,戴建华,王燕青,陈光辉,刘晓峰,苗福禄,白玲,陈玉林.肺癌组织中耐药相关基因的表达水平及其临床意义[J].中国肺癌杂志,2002,5(1):35-37. 被引量:15
  • 4ZHENG J N, MAT X, CAOJ Y, et al. Knockdown of Ki 67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells[J]. Life Science, 2006,78(7) :724 729.
  • 5ENDICOTT J A, LING V. The biochemistry of P glycoprotein mediated multidrug resistance [J].Ann Rev Biochem, 1989,58:137-171.
  • 6ARANCIAG, MOI.1NARIA, CAI.CABRINI A, etal. Intra cellular P-glycoprotcin in muhidrug resistant tumor cells[J]. ltal J Anat Embryol, 2001,106:59-68.
  • 7(~AIAMBERTI S, MARCHETTI A, BUTTITTA F, et al. Muhidrug resistance related genes and p53 expression in hu man non small cell lung cancer[J]. Anticancer Research 1998,18(40) :2973-2977.
  • 8BEER T W, ROWLANDS D C, CROCKER J, et al. Detec tion of lhe multidrug resistance marker P glycoprotein by im munohistochemistry in malignant lung tumours[J]. Thorax 1996,15:526-529.
  • 9曲延刚,纪祥瑞,唐爱萍.多药耐药相关蛋白在乳腺浸润性导管癌中的表达[J].青岛大学医学院学报,2007,43(1):70-71. 被引量:4
  • 10聂坤荣,李春海.肺癌谷胱甘肽硫转移酶表达的免疫组化研究[J].中华结核和呼吸杂志,1993,16(3):141-143. 被引量:14

二级参考文献93

共引文献49

同被引文献90

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部